Furthermore, preclinical studies in a pancreatic cancer model reveal that targeting DDR1 not only disrupts collagen architecture but also enhances chemotherapeutic efficacy and promotes immune cell infiltration. This evidence concerns the gene DDR1 and familial pancreatic carcinoma.